Septodont Ou Septodont SAS Ou Specialites Septodont

Septodont is pleased to announce the successful completion of its acquisition of a 51% interest in Inibsa. This operation follows the receipt of customary regulatory approvals and satisfaction of closing conditions. In this strategic transaction, Septodont has acquired a controlling stake in Inibsa, alongside Acteon, a Dentressangle portfolio company, as a strong partner and non-controlling shareholder. This acquisition represents another significant milestone in Septodont’s long term growth strategy. Olivier Schiller, CEO of the Septodont Group, commented: “This acquisition of control of Inibsa will expand Septodont’s development in dental products and help us further strengthen our geographical footprint. This is an important acquisition for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams”. Inibsa is a global pharmaceutical group located in Spain specializing in the production of injectable anesthetics and in the distribution of a large portfolio of dental products.

Inibsa, the global pharmaceutical group specializing in the development and manufacturing of products for dental practitioners, today announced that Septodont and Acteon will become the shareholders of Inibsa. The transaction is subject to the satisfaction of customary closing conditions including regulatory approvals, which are expected to be completed before the end of the year.  The announcement marks an important milestone in Inibsa’s growth journey. This project with two new shareholders will enable the group to further accelerate its growth and development, in Iberia and worldwide. Through this investment, Septodont as the majority shareholder will acquire a controlling stake in Inibsa, alongside Acteon, as a strong partner and non-controlling shareholder.  “This is a significant step forward for our company and those we serve. Since our founding in 1948, more than 75 years ago, Inibsa has been growing continuously. While we are proud of the company that we have built, we are also excited about our future with our new shareholders”, declared Eduard Lopez, General Manager of Inibsa. “In Septodont and Acteon, we have strong partners who are committed to strengthening and growing our business.” “We are excited to support Inibsa’s development through this investment. The acquisition of Inibsa is an important one for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams”, added Olivier Schiller, CEO of Septodont. “It will also enhance our own development in dental products and help us further strengthen our geographical footprint”. “We are thrilled to invest in Inibsa alongside Septodont. It will give Acteon the opportunity to strengthen its manufacturing position in the area of dental pharmaceutical products in Europe and Asia”, added Markus Boehringer, CEO of Acteon. "Our shareholders were very supportive of this acquisition, which is the perfect complement of our current strategy, focusing on effective innovation, enhancing our customer service and strengthening operational capabilities.”

本文数据来自于CPM新药研发监测数据库（cpm.pharmadl.com）。感觉器官用药2022年NMPA批准的进口消化系统用药，共计28个（按照注册证号分类），获批品种最多的企业是Santen Pharmaceutical Co Ltd（11个）；涉及靶点排名前三的是GCCR（9个）、PTGFR（3个）、P2RY2（2个）。在政策相关度方面，2022年获批的进口消化系统用药中，2022国家医保目录品种共有20个，没有带量采购招标品种。生殖系统用药2022年NMPA批准的进口消化系统用药，共计15个（按照注册证号分类），获批品种最多的企业是Jenapharm GmbH & Co KG（3个）；涉及靶点排名前三的是ESR1（7个）、CYP51A1（4个）。在政策相关度方面，2022年获批的进口消化系统用药中，2022国家医保目录品种共有7个，没有带量采购招标品种。麻醉药及其辅助用药2022年NMPA批准的进口消化系统用药，共计3个（按照注册证号分类），获批品种较多的企业有Septodont（2个）、Powder Pharmaceuticals Inc（1个）。在政策相关度方面，2022年获批的进口消化系统用药中，2022国家医保目录品种共有2个，没有带量采购招标品种。免疫调节剂2022年NMPA批准的进口消化系统用药，共计10个（按照注册证号分类），获批品种较多的企业有诺华（3个）、辉瑞（3个）、Swedish Orphan Biovitrum AB（3个）；涉及靶点排名前三的是IFNG（3个）、JAK1（3个）、mTOR（2个）。在政策相关度方面，2022年获批的进口消化系统用药中，2022国家医保目录品种共有7个，没有带量采购招标品种。年度发布2023年《全球药研新动态》《中国医院市场用药格局》（2023版）2023年《数图药讯》权威发布2021年度中国医药工业百强榜单解读中国仿制药发展报告（2022版）医药行业专项报告中国医药中间体和原料药行业调研报告中国非甾体抗炎类原料药市场调研报告中国祛痰类原料药市场调研报告中国钙拮抗剂类原料药市场调研报告中国血管紧张素Ⅱ受体拮抗剂类原料药市场调研报告中国口服血糖调节类原料药市场调研报告中国中枢兴奋类原料药市场调研报告中国抗痛风类原料药市场调研报告中国脑血管病类原料药市场调研报告END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001